Rutherrin It was crystal clear many years’ ago - with the April the 8th paper simply undeniable confirmation - that RUTHERRIN so spectacularly outshines TLD-1433 in every department - safety efficacy capability - that it poses a number of existential questions the first and blindingly obvious of which is why ever use TLD-1433 alone in any setting - including the current NMIBC Trial - if Rutherrin can be used instead?
The equally obvious answer is that Rutherrin is not being allowed to be used and more concerning now is the reluctance of the Company even to refer to it by name.
Have they been warned off pre-incubation (the success of which represents a game-changing threat to Big Pharma) to the extent that they are now reduced as they have been to conflating the endogenous take up of Tf by TLD-1433 with Rutherrin as if the entirely different resultants are the same thing? They are not!
A radical new paradigm in cancer treatment is being hidden and will given time and inaction be outflanked even by hugely more problematic technologies.This treatment has been parked up for years to date with less and less information being provided by the Company as to where it is going.
No denying the scope for TLD-1433 on its`own in a number of cancers but for blue sky it is Rutherrin or Bust - and the share price tells you which one the market thinks that it will be.